Skip to main content
Veronika Bachanova, MD, Oncology, Minneapolis, MN

VeronikaBachanovaMDPhD

Oncology Minneapolis, MN

Hematologic Oncology

Professor of Medicine, University of Minnesota Medical School, Section Head for Malignant Hematology, Director of Hematologic Malignancies Tissue Bank

Dr. Bachanova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bachanova's full profile

Already have an account?

  • Office

    516 Delaware St SE Ste 5100
    University OT Minnesota Physicians
    Minneapolis, MN 55455
    Phone+1 612-626-2663

Summary

  • I am a board certified hematologist/oncologist specializing in bone marrow transplantation, cellular therapies and immunotherapies to treat lymphoma and leukemia. My mission to make new promising therapies available to all patients and offer compassionate care at the highest standards. I lead CAR-T program at University of Minnesota.

Education & Training

  • University of Minnesota
    University of MinnesotaFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Henry Ford Health/Henry Ford Hospital
    Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1995 - 1998
  • Comenius University
    Comenius UniversityClass of 1992

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2006 - 2025
  • TX State Medical License
    TX State Medical License 1998 - 2005
  • MI State Medical License
    MI State Medical License 1998 - 1999

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment Kinetics  
    Erhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
  • Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or Relapse  
    Patrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood

Abstracts/Posters

  • Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT)
    Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
    Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
    Veronika Bachanova, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Advancement in Research Improves Checkpoint Inhibitor Therapy for Cancer
    Advancement in Research Improves Checkpoint Inhibitor Therapy for CancerJune 27th, 2024
  • Immunosuppressant Ruxolitinib Boosts Checkpoint Inhibitor Response in Patients with Hodgkin Lymphoma, Phase I Data Show
    Immunosuppressant Ruxolitinib Boosts Checkpoint Inhibitor Response in Patients with Hodgkin Lymphoma, Phase I Data ShowJune 20th, 2024
  • Clinical Challenges: Managing Hodgkin's in Pregnancy
    Clinical Challenges: Managing Hodgkin's in PregnancyDecember 18th, 2020
  • Join now to see all